title: Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.
abstract: Autologous hematopoietic cell transplantation (auto-HCT) is performed to treat relapsed and recurrent malignant disorders and as part of initial therapy for selected malignancies. This study evaluated changes in use, techniques, and survival in a population-based cohort of 68,404 patients who underwent first auto-HCT in a US or Canadian center between 1994 and 2005 and were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The mean annual number of auto-HCTs performed was highest during 1996-1999 (6948), and decreased subsequently 2000-2003 (4783), owing mainly to fewer auto-HCTs done to treat breast cancer. However, the mean annual number of auto-HCTs increased from 5278 annually in 1994-1995 to 5459 annually in 2004-2005, reflecting increased use for multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Despite an increase in the median recipient age from 44 to 53 years, there has been a significant improvement in overall survival (OS) from 1994 to 2005 in patients with chemotherapy-sensitive relapsed non-Hodgkin lymphoma (day +100 OS, from 85% to 96%; 1-year OS, from 68% to 80%; P < .001) and chemotherapy-sensitive multiple myeloma (day +100 OS, from 96% to 98%; 1-year OS, from 83% to 92%; P < .001). This improvement in OS was most pronounced in middle-aged (>40 years) and older (>60 years) individuals.
authors: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors: Philip L
authors: PL
authors: McCarthy
authors: Theresa
authors: T
authors: Hahn
authors: Anna
authors: A
authors: Hassebroek
authors: Christopher
authors: C
authors: Bredeson
authors: James
authors: J
authors: Gajewski
authors: Gregory
authors: G
authors: Hale
authors: Luis
authors: L
authors: Isola
authors: Hillard M
authors: HM
authors: Lazarus
authors: Stephanie J
authors: SJ
authors: Lee
authors: Charles F
authors: CF
authors: Lemaistre
authors: Fausto
authors: F
authors: Loberiza
authors: Richard T
authors: RT
authors: Maziarz
authors: J Douglas
authors: JD
authors: Rizzo
authors: Steven
authors: S
authors: Joffe
authors: Susan
authors: S
authors: Parsons
authors: Navneet S
authors: NS
authors: Majhail
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality* / Q000706:statistics & numerical data / Q000639:trends*; D006689:Hodgkin Disease / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007223:Infant; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009656:North America; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D014182:Transplantation, Autologous
references: N Engl J Med. 1996 Jul 11;335(2):91-7
references: 8649495
references: Blood. 2011 Jun 9;117(23):6063-73
references: 21447828
references: J Clin Oncol. 2008 Jan 20;26(3):480-92
references: 18056678
references: Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:53-8
references: 18336402
references: J Clin Oncol. 2010 Sep 20;28(27):4184-90
references: 20660832
references: N Engl J Med. 2012 May 10;366(19):1770-81
references: 22571201
references: Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S20-5
references: 23290439
references: Bone Marrow Transplant. 2001 Feb;27(4):405-12
references: 11313670
references: Health Serv Res. 2011 Dec;46(6pt1):1762-77
references: 21790588
references: Blood. 2012 Jan 26;119(4):940-8
references: 22160383
references: Cancer Treat Rev. 2007 Jun;33(4):325-37
references: 17382477